The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia

Bone Marrow Transplantation

Volumn 19, Issue 9, 1997, Pages 891-897

  Lowdell, M W ^a   Ray, N ^a   Craston, R ^a   Corbett, T ^a   Deane, M ^a   Prentice, H G ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

ABMT; Cytotoxicity; GVL; Immunotherapy; NK cells

Indexed keywords

ALPHA INTERFERON;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CASE REPORT; CYTOLYSIS; CYTOTOXICITY; FEMALE; HUMAN; LEUKEMIA CELL; LEUKEMIA REMISSION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RELAPSE;

EID: 0030981650     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700756     Document Type: Article

References (26)

1. Bacigalupo A, Van Lint MT, Occhini D et al. Increased risk of leukaemia relapse with high-dose cyclosporin A after allogeneic marrow transplantation for acute leukaemia. Blood 1991; 177: 1423-1428.
2. + T cells to graft-versus-host disease and graft-versus-leukaemia reactivity after transplantation of MHC compatible bone marrow. Bone Marrow Transplant 1991; 8: 51-58.
3. OKunewick JP, Kociban DL, Machen LL, Buffo MJ. Comparison of the effects of CD3 and CD5 donor T cell depletion on graft-versus-leukaemia in a murine model for MHC-matched unrelated-donor transplantation. Bone Marrow Transplant 1994; 13: 11-17.
4. Hercend T, Takvorian T, Nowill A et al. Characterisation of natural killer cells with antileukaemia activity following allogeneic bone marrow transplantation. Blood 1986; 67: 722-728.
5. Rettie JE, Gottlieb D, Heslop H et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351-1358.
6. Lotzova E, Savaray CA, Herberman RB. Induction of NK cell activity against fresh human leukaemia in culture with interleukin 2. J Immunol 1987; 138: 2718-2727.
7. Robertson LE, Denny AW, Huh YO et al. Natural killer cell activity in chronic lymphocytic leukaemia patients treated with fludarabine. Cancer Chemother Pharmacol 1996; 37: 445-450.
8. Lowdell MW, Shamim F, Hamon M et al. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Exp Hematol 1995; 23: 1530-1534.
9. + natural killer cells after bone marrow transplantation. Blood 1992; 79: 3239-3244.
10. Scheid C, Pettengell R, Ghielmini M et al. Time course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 15: 901-906.
11. Tratkiewicz JA, Szer J. Loss of natural killer activity as an indicator of relapse in acute leukaemia. Clin Exp Immunol 1990; 80: 241-246.
12. Slezak SE, Horan PK. Cell-mediated cytotoxicity. A highly sensitive and informative flow cytometric assay. J Immunol Meth 1989; 117: 205-214.
13. Radosevic K, Garritsen H, VanGraft M et al. A simple and sensitive flow cytometric assay for the determination of the cytotoxic activity of human natural killer cells. J Immunol Meth 1990; 153: 81-89.
14. Hatam L, Schuval S, Bonagura VR. Flow cytometric analysis of natural killer cell function as a clinical assay. Cytometry 1994; 16: 59-68.
15. Lowdell MW, Galatowicz G, Prentice HG. A novel flow cytometric NK/LAK cell assay utilising physiological effector: target cell ratios. Br J Haematol 1994; 86 (Suppl. 1): 30 (Abstr. 111).
16. Watson JV. Immunofluorescence data. In: Watson JV (ed). Flow Cytometry Data Analysis - Basic Concepts and Statistics. Cambridge University Press: Cambridge, 1992, pp 101-124.
17. +/HLA-DR+ve cells in HIV-1 infected patients. AIDS 1991; 5: 813-819.
18. Barnes DWH, Loutit JF. Treatment of murine leukaemia with X-rays and homologous bone marrow II. Br J Haematol 1957; 3: 241-248.
19. Lowdell MW, Craston R, Prentice HG. Understanding the graft-versus-leukaemia reaction: progress towards the immunotherapy of leukaemia. Hematology (in press).
20. Champlin R, Pasweg J, Horowitz M. T-cell depleted (TCD) BMT for leukaemia patients with donors other than HLA-identical siblings. Blood 1995; 86 (Suppl. 1): 94a (Abstr. 362).
21. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukaemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-4343.
22. Maino VC, Suni MA, Ruitenberg JJ. Rapid flow cytometric method for measuring lymphocyte subset activation. Cytometry 1995; 20: 127-133.
23. Kos FJ, Engleman EG. Requirement for natural killer cells in the induction of cytotoxic T cells. J Immunol 1995; 155: 578-584.
24. Lanier LL, Buck DW, Rhodes L et al. Interleukin-2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu 23 activation antigen. J Exp Med 1988; 167: 1572-1585.
25. Chambers WH, Brissette-Storkus CS. Hanging in the balance: natural killer cell recognition of target cells. Chem Biol 1995; 2: 429-433.
26. Lanier LL, Phillips JH. Inhibitory MHC class I receptors on NK and T cells. Immunol Today 1996; 17: 86-91.